Scroll

rilmenidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
alpha-2 adrenoreceptor agonists	2381	54187-04-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: rilmenidine oxaminozoline rilmenidene rilmenidine phosphate rilmenidine dihydrogen phosphate	Oxazole derivative that acts as an agonist for ALPHA-2 ADRENERGIC RECEPTORS and IMIDAZOLINE RECEPTORS. It is used in the treatment of HYPERTENSION. Molecular weight: 180.25 Formula: C10H16N2O CLOGP: 1.42 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 33.62 ALOGS: -2.13 ROTB: 3

Molecule

Description

Molfile Inchi Smiles

Synonyms:

rilmenidine
oxaminozoline
rilmenidene
rilmenidine phosphate
rilmenidine dihydrogen phosphate

Oxazole derivative that acts as an agonist for ALPHA-2 ADRENERGIC RECEPTORS and IMIDAZOLINE RECEPTORS. It is used in the treatment of HYPERTENSION.

Molecular weight: 180.25
Formula: C10H16N2O
CLOGP: 1.42
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 33.62
ALOGS: -2.13
ROTB: 3

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	4.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	7.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.90 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	8.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	328.41	32.34	209	4071	263206	63221536
Lactic acidosis	236.70	32.34	91	4189	38196	63446546
Hyperkalaemia	137.90	32.34	69	4211	54134	63430608
Allergic reaction to excipient	100.39	32.34	18	4262	355	63484387
Hyponatraemia	87.29	32.34	67	4213	111833	63372909
Mixed liver injury	75.76	32.34	23	4257	4712	63480030
Isosthenuria	75.65	32.34	12	4268	108	63484634
Rhabdomyolysis	72.51	32.34	42	4238	43909	63440833
Pyelitis	68.28	32.34	12	4268	210	63484532
Bladder hypertrophy	67.34	32.34	12	4268	228	63484514
Toxic skin eruption	66.74	32.34	27	4253	12858	63471884
Electrocardiogram PR shortened	65.37	32.34	12	4268	271	63484471
Multiple organ dysfunction syndrome	62.62	32.34	42	4238	56710	63428032
Angioedema	54.12	32.34	36	4244	47929	63436813
Creatinine renal clearance increased	50.03	32.34	11	4269	628	63484114
Carbohydrate antigen 15-3 increased	45.85	32.34	12	4268	1436	63483306
Eye oedema	45.28	32.34	12	4268	1508	63483234
Primary hyperaldosteronism	44.86	32.34	7	4273	56	63484686
Carcinoembryonic antigen increased	43.50	32.34	12	4268	1753	63482989
Drug reaction with eosinophilia and systemic symptoms	42.08	32.34	27	4253	33809	63450933
Renin decreased	40.78	32.34	7	4273	106	63484636
Bradycardia	40.58	32.34	36	4244	73191	63411551
Prevertebral soft tissue swelling of cervical space	39.96	32.34	6	4274	36	63484706
Fall	39.91	32.34	84	4196	392250	63092492
Peripheral artery haematoma	39.55	32.34	6	4274	39	63484703
Ischaemic stroke	37.35	32.34	20	4260	17937	63466805
Myoclonus	36.77	32.34	19	4261	15849	63468893
Blood aldosterone increased	36.68	32.34	7	4273	196	63484546
Intestinal transit time abnormal	36.40	32.34	6	4274	70	63484672
Overdose	35.15	32.34	41	4239	115037	63369705
Hypotension	34.48	32.34	64	4216	272540	63212202
Psychomotor retardation	34.22	32.34	12	4268	3858	63480884
Hypochloraemia	33.17	32.34	10	4270	1999	63482743
Cholestasis	32.96	32.34	22	4258	29412	63455330
Breast cancer recurrent	32.87	32.34	12	4268	4329	63480413

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	161.71	27.39	146	2256	304842	34649687
Cerebral haematoma	63.28	27.39	20	2382	4595	34949934
Lactic acidosis	61.56	27.39	35	2367	34737	34919792
Hyperkalaemia	61.12	27.39	45	2357	69344	34885185
Necrotising oesophagitis	51.16	27.39	11	2391	555	34953974
Hypovolaemic shock	47.54	27.39	18	2384	7067	34947462
Hemiplegia	33.77	27.39	14	2388	6958	34947571
Product name confusion	29.60	27.39	5	2397	67	34954462
Tubulointerstitial nephritis	28.91	27.39	18	2384	21006	34933523
Hypokalaemia	28.67	27.39	27	2375	58187	34896342
Pemphigoid	27.71	27.39	13	2389	8653	34945876
Wrong strength	27.53	27.39	5	2397	104	34954425

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	432.06	25.35	353	6428	519051	79218556
Lactic acidosis	261.96	25.35	125	6656	70234	79667373
Hyperkalaemia	177.11	25.35	114	6667	114284	79623323
Allergic reaction to excipient	97.24	25.35	18	6763	334	79737273
Hyponatraemia	78.97	25.35	86	6695	177762	79559845
Isosthenuria	72.56	25.35	12	6769	111	79737496
Cerebral haematoma	62.41	25.35	24	6757	7918	79729689
Electrocardiogram PR shortened	61.30	25.35	12	6769	303	79737304
Pyelitis	60.28	25.35	12	6769	331	79737276
Mixed liver injury	56.35	25.35	22	6759	7556	79730051
Bladder hypertrophy	52.47	25.35	12	6769	647	79736960
Toxic skin eruption	52.05	25.35	29	6752	22264	79715343
Angioedema	50.84	25.35	46	6735	75989	79661618
Rhabdomyolysis	49.47	25.35	52	6729	103079	79634528
Hypovolaemic shock	49.21	25.35	23	6758	12253	79725354
Carbohydrate antigen 15-3 increased	45.53	25.35	12	6769	1167	79736440
Pemphigoid	44.38	25.35	23	6758	15292	79722315
Ischaemic stroke	43.84	25.35	30	6751	33101	79704506
Creatinine renal clearance increased	43.58	25.35	11	6770	902	79736705
Overdose	43.34	25.35	65	6716	184141	79553466
Hypokalaemia	43.04	25.35	57	6724	143983	79593624
Multiple organ dysfunction syndrome	42.93	25.35	52	6729	120194	79617413
Necrotising oesophagitis	41.41	25.35	11	6770	1102	79736505
Blood aldosterone increased	40.21	25.35	8	6773	220	79737387
Eye oedema	38.89	25.35	12	6769	2051	79735556
Prevertebral soft tissue swelling of cervical space	38.57	25.35	6	6775	36	79737571
Renin decreased	38.39	25.35	7	6774	119	79737488
Intracranial haematoma	38.38	25.35	10	6771	930	79736677
Carcinoembryonic antigen increased	38.08	25.35	12	6769	2197	79735410
Primary hyperaldosteronism	36.90	25.35	7	6774	149	79737458
Fall	36.22	25.35	107	6674	487522	79250085
Intestinal transit time abnormal	35.01	25.35	6	6775	70	79737537
Breast cancer recurrent	34.57	25.35	12	6769	2965	79734642
Hepatic cytolysis	34.54	25.35	24	6757	27127	79710480
Hemiplegia	33.69	25.35	19	6762	14920	79722687
Renal failure	32.58	25.35	60	6721	200908	79536699
Drug reaction with eosinophilia and systemic symptoms	31.87	25.35	33	6748	64211	79673396
Peripheral artery haematoma	31.75	25.35	6	6775	125	79737482
Hypotension	31.14	25.35	95	6686	440222	79297385
Drug interaction	30.70	25.35	91	6690	415092	79322515
Rash maculo-papular	29.99	25.35	30	6751	56048	79681559
Myoclonus	29.57	25.35	22	6759	27638	79709969
Intestinal haemorrhage	28.76	25.35	13	6768	6413	79731194
Hypochloraemia	28.67	25.35	10	6771	2505	79735102
Vascular resistance systemic	27.26	25.35	4	6777	15	79737592
Bradycardia	26.54	25.35	44	6737	135513	79602094
Blood pressure inadequately controlled	26.08	25.35	12	6769	6165	79731442
Psychomotor retardation	26.07	25.35	12	6769	6172	79731435

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C02AC06	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIADRENERGIC AGENTS, CENTRALLY ACTING Imidazoline receptor agonists
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D058647	Adrenergic alpha-2 Receptor Agonists
MeSH PA	D000316	Adrenergic alpha-Agonists
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D013565	Sympatholytics

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.22	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN	Ki	7.44	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN	Ki	5.05	CHEMBL
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN	Ki	7.37	CHEMBL
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN	Ki	7.90	CHEMBL
Nischarin	Membrane receptor	Q9Y2I1	NISCH_HUMAN	Ki	7.23	CHEMBL
Nischarin	Unclassified		NISCH_RAT	Ki	7.95	CHEMBL

External reference:

ID	Source
D08482	KEGG_DRUG
85409-38-7	SECONDARY_CAS_RN
C0140591	UMLSCUI
CHEBI:8862	CHEBI
CHEMBL289480	ChEMBL_ID
DB11738	DRUGBANK_ID
D000077769	MESH_DESCRIPTOR_UI
68712	PUBCHEM_CID
5846	INN_ID
P67IM25ID8	UNII
236379	RXNORM
005772	NDDF
005773	NDDF
765332006	SNOMEDCT_US
765333001	SNOMEDCT_US

Pharmaceutical products:

None